Hematology & Oncology Doctors in Kalamazoo, MI Accepting Medicare

6 Hematology & Oncology doctors found. Showing 1 - 6

Dr. Sunil Nagpal, M.D. Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 805 John Street, Kalamazoo, MI 49007 Phone: 269-286-7170

Dr. Raymond Sterling Lord, M.D. Internal Medicine - Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 200 N Park St, Kalamazoo, MI 49007 Phone: 269-373-7464

Keith Dale Bailey, MD Internal Medicine - Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 200 N Park St, Kalamazoo, MI 49007 Phone: 269-373-7488    Fax: 269-373-0123

Bharat L Agrawal, MD Internal Medicine - Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 200 N Park St, Kalamazoo, MI 49007 Phone: 269-373-7449    Fax: 269-373-0123

Marcia Liepman, MD Internal Medicine - Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 200 N Park St, Kalamazoo, MI 49007 Phone: 269-382-2500    Fax: 269-373-7478

Sanja Kaluza, M.D. Internal Medicine - Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 200 N Park St, Kalamazoo, MI 49007 Phone: 269-373-7442    Fax: 269-373-0123

News Archive

UI orthopedics researchers working on injectable, bioactive gel that can repair cartilage damage

Knee injuries are the bane of athletes everywhere, from professionals and college stars to weekend warriors. Current surgical options for repairing damaged cartilage caused by knee injuries are costly, can have complications, and often are not very effective in the long run. Even after surgery, cartilage degeneration can progress leading to painful arthritis.

VIA Pharmaceuticals receives NASDAQ delisting notice

VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on December 29, 2009, it received a written notice from the listing qualifications staff of the NASDAQ Stock Market ("NASDAQ") informing the Company that trading of the Company's common stock would be suspended prior to the open of business on January 4, 2010 and that NASDAQ would initiate procedures to delist the Company's common stock.

Basic cancer research at Creighton yields promising results for diagnosing, treating asthma

What started as basic cancer research at Creighton University has yielded promising results for diagnosing and treating asthma - and the National Institutes of Health (NIH) agrees, investing nearly $1.5 million in Creighton to find out more.

Health risks associated with H1N1 vaccine investigated

Results from two studies published in JAMA show that the H1N1 vaccination is associated with a small, but significant, increase in risk for Guillain-Barré syndrome in adults, but does not increase the risk for birth defects or problems when given to pregnant women.

Read more Medical News

› Verified 7 days ago